Mechanisms of Anticancer Drug Action

• 5685 · PDF WRN抑制后的有丝分裂错误耐受性存活可通过持续激活纺锤体检查点加以克服 Mitotic error-tolerant survival following WRN inhibition is overcome by sustained spindle checkpoint activation Sungmin Cho, Joong-Bae Ahn, Sang Joon Shin
• 5686 · PDF SF3B1抑制通过破坏ATRX剪接并诱导细胞周期阻滞抑制前列腺癌 SF3B1 inhibition suppresses prostate cancer by disrupting ATRX splicing and inducing cell cycle arrest Linyue Li, Weijian Ding, Zhihao Nie, Congrong Jiang, Ruining Zhao, Siyuan Xia, Baotong Zhang
• 5687 · PDF 靶向KIFC1在小细胞肺癌中诱导后期灾变 Targeting KIFC1 induces anaphase catastrophe in small cell lung cancer Minemichi Toda, Natsuki Nakagawa, Masakatsu Tokunaga, Mirei Ka, Takahiro Iida, Hiroaki Ikushima, Takahiro Ando, Akiko Kunita, Kousuke Watanabe, Xi Liu, Ethan Dmitrovsky, Hidenori Kage, Masanori Kawakami
• 5688 · PDF 对TRIP13和Aurora A的合成致死靶向在Rb缺陷型癌细胞中诱导有丝分裂DNA损伤及并发的焦亡-凋亡性细胞死亡 Synthetic lethal targeting of TRIP13 and Aurora A induces mitotic DNA damage and concurrent pyroptotic-apoptotic cell death in Rb-deficient cancer cells Lacin Yapindi, Soma Ghosh, Li Shen, Lixia Diao, Jing Wang, Faye M. Johnson
• 5689 · PDF 流式细胞术分析新型苯并吡喃衍生物（SK6）在MCF-7乳腺癌细胞中诱导的细胞周期阻滞和凋亡 Flow-cytometric analysis of cell-cycle arrest and apoptosis induced by a novel benzopyran derivative (SK6) in MCF-7 breast cancer cells Mariappan Gurusamy, Razia Shaika, Brijesh Sharma
• 5690 · PDF 内切核酸酶FEN1抑制在神经母细胞瘤中的疗效机制 Mechanisms of efficacy of endonuclease FEN1 inhibition in neuroblastoma Carla S. Sampaio, Eric Wu, Madison Cinelli, Erica Steen, Andrew Shiau, Richard Kolodner, Jean Wang, Peter E. Zage
• 5691 · PDF 全氟和多氟烷基物质（PFAS）促进遗传背景不同的肾癌细胞系的增殖和迁移 Per and polyfluoroalkyl substances (PFAS) promote proliferation and migration in genetically distinct kidney cancer cell lines Rakesh Kumar Arya, Mia Sand, Sahab Ram Dewala, Can Aydogdu, Gabriela M. Diaz, Christopher Weight, Riccardo Autorino, Abhishek Chakraborty, Jacob M. Knorr, Joseph M. K. Irudayaraj, Laura Bukavina
• 5692 · PDF 托芬那酸抗增殖活性的机制 Mechanism of antiproliferative activity of tolfenamic acid Fatima Rehman, Hesham Syed, Umesh T. Sankpal
• 5693 · PDF CDK4/6抑制剂与HDAC抑制剂在胰腺癌中的协同作用可克服自噬 Synergy of a CDK4/6 inhibitor and an HDAC inhibitor in pancreatic cancer overcomes autophagy Vikas Dukhande, Shraddha Bhutkar, Anjali Yadav
• 5694 · PDF SQLE抑制剂通过引起ER应激触发卵巢癌细胞凋亡 SQLE inhibitor triggers ovarian cancer apoptosis by causing ER stress Cheng Chi, Lei Sun, Mahmuda Akter, Shuang Huang
• 5695 · PDF CyTOF分析靶向治疗联合标准治疗对尤因肉瘤肿瘤亚群的作用 CyTOF analysis of targeted therapy in addition to standard of care against Ewing sarcoma tumor subpopulations Kaitlyn H. Smith, Lucy Endean, Kimberly Q. McKinney, Poornima Gourabathini, Kenzie Wells, Jeffrey Huo, Erin M. Trovillion, Javier Oesterheld
• 5696 · PDF RAS(ON)多选择性抑制剂刺激RAS-GTP水解为RAS-GDP，并在G12突变肿瘤中与KRAS(OFF)抑制剂产生协同联合获益 RAS(ON) multi-selective inhibitors stimulate the hydrolysis of RAS-GTP to RAS-GDP and drive synergistic combination benefit with KRAS(OFF) inhibitors in G12 mutant tumors Hiroyuki Matsubara, Alec Millner, Yu C. Yang, Jun Sun, Stephanie Change, Shelby L. Steele, Marini Thian, Miguel Sandoval, Zhican Wang, Mike Flagella, Mallika Singh, Jingjing Jiang, Jacqueline A. M. Smith, Ryan B. Corcoran, Kyle J. Seamon
• 5697 · PDF EZH2抑制上调GD2以增强尤因肉瘤的抗GD2免疫治疗 EZH2 inhibition upregulates GD2 to enhance anti-GD2 immunotherapy in Ewing sarcoma Kenzie Wells, Kimberly Q. McKinney, Kaitlyn H. Smith, Poornima Gourabathini, Jeffrey Huo, Erin M. Trovillion, Javier Oesterheld
• 5698 · PDF 在淋巴瘤中利用MYC致癌应激实现治疗获益 Exploiting MYC Oncogenic Stress for Therapeutic Benefit in Lymphoma Smriti Kanangat, James D. Phelan, Louis Staudt
• 5699 · PDF Tegavivint直接靶向TBL1以抑制b-catenin核内致癌活性 Tegavivint directly targets TBL1 to inhibit b-catenin nuclear oncogenic activity Aundrietta Duncan, Prashi Jain, Elena Ramirez, Julissa Simmons, Mahtab Youseffi, Stephen Horrigan
• 5702 5702 一种基于图像的方法用于可视化ADC在患者来源类器官中的内化与细胞毒性 An image-based approach to visualize ADC internalization and cytotoxicity in patient-derived organoids Daniele Mori, Javier Frias Aldeguer, Rene Overmeer, Sylvia F. Boj
• 5703 5703 通过患者来源类器官药物筛选剖析骨肉瘤的趋同进化与分子适应 Profiling osteosarcoma convergent evolution and molecular adaptations through patient-derived organoid drug-screening Kailee A. Rutherford, Jonathan N. Levi, Summer Norris, Alice Soragni
• 5704 · PDF 临床前研究揭示蛋白酶介导的载荷释放及免疫肿瘤学/免疫调节效应促成HLX43的抗肿瘤活性 Preclinical studies reveal that protease-mediated payload release and immuno-oncology/immunomodulatory effects contribute to the antitumor activity of HLX43 Lixin Feng, Jijun Yuan, Wan-Jen Yang, Chenqiang Jia, Ge Song, Qingyu Wang, Jun Zhu
• 5705 · PDF 利用单细胞多组学分析识别前列腺癌中雄激素剥夺诱导的反应 Identifying androgen deprivation-induced responses in prostate cancer with single cell multiomic analysis Anni Perämäki, Iina Koivisto, Alfonso Urbanucci, Frank Claessens, Mikael Marttinen, Matti Nykter
• 5706 · PDF 建模肿瘤治疗电场（TTFields）治疗使用时间与中断模式对治疗结局的影响 Modeling the influence of Tumor Treating Fields (TTFields) treatment usage time and break patterns on therapeutic outcomes Rotem Engelman, Daria Gerasimova, Talya Borkum, Eyal Dor-On, Itai Tzchori, Hila Fishman, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti, Na Tosha N. Gatson
• 5707 · PDF GEM144（一种POLA1-HDAC11双重抑制剂）在结直肠癌模型中的作用机制 Mechanism of action of GEM144, a POLA1-HDAC11 dual inhibitor, in colorectal cancer models Rana Abdel-Samad, Avery Lazaro, Maura Mack, Berthe Hayar, Claudio Pisano, Nadine Darwiche
• 5708 · PDF 双重靶向PDPK1和突变型BRAFV600E具有合成致死性 Dual targeting of PDPK1 and mutated BRAFV600E is synthetically lethal Tejinder Pal Khaket, Chandrayee Gosh, Zhongyue Yang, Electron Kebebew

在会议检索中浏览本分会场